Pipeline — registered trials by phase
Amphetamine Induced Adult Respiratory Distress Syndrome
— · Burns, Acute Lung Injury, Acute Respiratory Distress Syndrome · Completed · est. 2020-01-01
Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection
— · COVID-19, Diabetes Mellitus, COVID-19 Pneumonia · Completed · est. 2022-12-30
Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
— · Acute Kidney Injury · Completed · est. 2022-02-12
Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
— · Pterygium · Completed · est. 2012-04
Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention
— · Lactate Blood Increase, Trauma Blunt, Trauma, Secondary · Completed · est. 2022-01-01
Management and Removal of Foreign Bodies in the Emergency Department
— · Rectal Foreign Body, Rectal Perforation, Colonic Perforation · Completed · est. 2021-12-08
Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
— · Burns, Ascorbic Acid Deficiency, Burn Shock · Completed · est. 2021-01-08
ABO Blood Group Type Association With COVID-19 Severity
— · COVID-19, Blood Group Antigen Abnormality, Blood Group Incompatibilities · Completed · est. 2023-05-10
Extremity Trauma At a Level 1 Trauma Center
— · Trauma Injury, Trauma Blunt, Vascular Trauma · Completed · est. 2024-01-01
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
— · Hypertriglyceridemia, Familial Chylomicronemia · Completed · est. 2021-02-11
Study of ARO-AAT in Normal Adult Volunteers
— · Alpha 1-Antitrypsin Deficiency · Completed · est. 2018-10-23
A First-In-Human Study of ARO-033 in Adult Participants
— · Age-related Macular Degeneration · Recruiting · est. 2028-07-01
Study of ARO-CFB in Adult Healthy Volunteers
— · IgA Nephropathy · Completed · est. 2025-03-31
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
— · Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia · Completed · est. 2021-05-17
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
— · Clear Cell Renal Cell Carcinoma · Completed · est. 2022-01-24
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
— · Healthy · Completed · est. 2016-08
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
— · Spinocerebellar Ataxia Type 2 · Active Not Recruiting · est. 2026-12
Study of ARO-RAGE in Healthy Subjects
— · Asthma · Completed · est. 2024-02-08
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
— · Healthy · Completed · est. 2014-09
Azithromycin Before Induction
— · Infections · Recruiting · est. 2026-08-07
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
— · Hyperlipidemia; Mixed · Recruiting · est. 2026-09-30
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
— · Hepatitis B · Completed · est. 2020-04-23
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
— · Severe Hypertriglyceridemia · Completed · est. 2023-03-09
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
— · Idiopathic Pulmonary Fibrosis · Completed · est. 2025-09-05
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
— · Asthma · Completed · est. 2025-04-16
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
— · Obesity, Diabetes Mellitus, Type 2 · Recruiting · est. 2027-02
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
— · Metabolic Dysfunction-Associated Steatohepatitis · Not Yet Recruiting · est. 2029-10
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
— · Alzheimer Disease, Alzheimer Disease, Early Onset · Recruiting · est. 2027-06
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
— · Obesity · Recruiting · est. 2027-09-17
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
— · Asthma · Recruiting · est. 2027-12
Study of ARO-APOC3 in Adults With Dyslipidemia
— · Dyslipidemias · Completed · est. 2025-09-22
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
— · C3 Glomerulopathy, IgA Nephropathy · Completed · est. 2025-09-10
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
— · Mixed Dyslipidemia · Completed · est. 2022-08-30
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
— · Alpha 1-Antitrypsin Deficiency · Completed · est. 2021-11-08
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
— · Alpha 1-Antitrypsin Deficiency · Completed · est. 2022-04-28
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
— · Non-alcoholic Steatohepatitis · Completed · est. 2021-09-03
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
— · Mixed Dyslipidemia · Completed · est. 2023-02-10
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
— · Severe Hypertriglyceridemia · Recruiting · est. 2029-03
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
— · Hypertriglyceridemia · Completed · est. 2026-06-01
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
— · Homozygous Familial Hypercholesterolemia · Recruiting · est. 2028-07
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
— · Hemorrhagic Shock, Trauma Injury · Completed · est. 2024-07-29
Oral Calcium Supplementation in Labor
— · Uterine Contraction, Labor Complication, Labor Active Dilated Cm · Completed · est. 2025-05-30
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
— · Homozygous Familial Hypercholesterolemia · Active Not Recruiting · est. 2027-08-20
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
— · Hypertriglyceridemia · Active Not Recruiting · est. 2028-07
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
— · Severe Hypertriglyceridemia · Completed · est. 2026-06-12
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
— · Severe Hypertriglyceridemia · Completed · est. 2026-06-17
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
— · Familial Chylomicronemia · Completed · est. 2024-04-29
RedemploPlozasiran Sodium
Source: ClinicalTrials.gov (trials where Arrowhead is lead sponsor; 47 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- 8-K2026-08-04Current report (material event)
- 10-Q2026-08-04Quarterly report
- SCHEDULE 13G/A2026-07-31SCHEDULE 13G/A
- SCHEDULE 13G/A2026-07-27SCHEDULE 13G/A
- 8-K2026-06-16Current report (material event)
- S-82026-05-07Employee stock plan
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-05-06SCHEDULE 13G
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- SCHEDULE 13G2026-04-28SCHEDULE 13G
- SCHEDULE 13G/A2026-04-24SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-03-20Current report (material event)
- 10-Q2026-02-05Quarterly report
- 8-K2026-02-05Current report (material event)
- ARS2026-01-27Annual report to holders
- DEFA14A2026-01-27DEFA14A
- DEF 14A2026-01-27Proxy statement
- SCHEDULE 13G/A2026-01-21SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- 8-K2026-01-09Current report (material event)
- 424B52026-01-09Prospectus (offering)
- 424B52026-01-09Prospectus (offering)
- 305B22026-01-08305B2
- FWP2026-01-08FWP
- FWP2026-01-08FWP
- 424B52026-01-07Prospectus (offering)
- 424B52026-01-07Prospectus (offering)
- 8-K2026-01-06Current report (material event)
- S-3ASR2025-12-11S-3ASR
- 10-K2025-11-25Annual report
- 8-K2025-11-25Current report (material event)
- 8-K2025-11-18Current report (material event)
- 10-K/A2025-10-10Annual report (amended)
- 8-K2025-09-12Current report (material event)
- 8-K2025-09-11Current report (material event)
- 8-K2025-09-02Current report (material event)
- SCHEDULE 13D/A2025-08-15SCHEDULE 13D/A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.